Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of Re-election of directors and supervisors at the 2021 annual shareholders’ meeting

1.Date of occurrence of the change:2021/10/27
2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): Institutional director, natural-person director and natural-person supervisor.
3.Title and name of the previous position holder:
Director         Tessie Che
Director         Michael Chang
Director         Frank Chen, Representative of Hui Hong Investment Co. Ltd
Director         Tamon Tseng, Representative of Hui Hong Investment Co. Ltd
Director         Tony Chow, Representative of Hui Hong Investment Co. Ltd
Supervisor    Cheng-Wei Ma
4.Resume of the previous position holder:
Director         Tessie Che/ Chairperson of the Board and General Manager, Amaran Biotechnology, Inc.
Director         Michael Chang/ Chairperson of the Board and CEO, OBI Pharma Inc.
Director         Frank Chen/ Vice President, Investment Management Department and Special Assistant to President, Ruentex Group
Director         Tamon Tseng/ Special Assistant to the Legal Affairs Department, Ruentex Industries, Ltd.
Director         Tony Chow/ Senior Partner, Tony Chow & Co.
Supervisor    Cheng-Wei Ma/Senior Manager, Investment Management Department, Ruentex Group
5.Title and name of the new position holder:
Director         Tessie Che
Director         Michael Chang, Representative of OBI Pharma Inc.
Director         Frank Chen, Representative of OBI Pharma Inc.
Director         Ming-Tain Lai, Representative of OBI Pharma Inc.
Director         Tamon Tseng, Representative of Hui Hong Investment Co. Ltd
Supervisor    Wan-Fang Ting
6.Resume of the new position holder:
Director         Tessie Che/ Chairperson of the Board and General Manager, Amaran Biotechnology, Inc.
Director         Michael Chang/ Chairperson of the Board and CEO, OBI Pharma Inc.
Director         Frank Chen/ Vice President, Investment Management Department and Special Assistant to President, Ruentex Group
Director         Ming-Tain Lai/ Chief Scientific Officer, OBI Pharma Inc.
Director         Tamon Tseng/ Special Assistant to the Legal Affairs Department, Ruentex Industries, Ltd.
Supervisor    Wan-Fang Ting/ Manager, Investment Management Department, Ruentex Group
7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”): New appointment
8.Reason for the change: Full re-election of directors and supervisors in advance.
9.Number of shares held by the new position holder when elected:
Director         Tessie Che/ 759,517 shares
Director         Michael Chang/ 64,915,252 shares
Director         Frank Chen/ 64,915,252 shares
Director         Ming-Tain Lai/ 64,915,252 shares
Director         Tamon Tseng/ 5,468,391 shares
Supervisor    Wan-Fang Ting/ 0 shares
10.Original term (from __________ to __________): From April 23, 2019 to April 22, 2022
11.Effective date of the new appointment: 2021/10/27
12.Turnover rate of directors of the same term: Not applicable
13.Turnover rate of independent directors of the same term: Not applicable
14.Turnover rate of supervisors of the same term: Not applicable
15.Change in one-third or more of directors (Please enter “Yes” or “No”): Not applicable
16.Any other matters that need to be specified: None